At the time of the St. Gallen Conference 2017, there was still a lack of scientific data to decide for which patients adjuvant systemic therapy should be recommended after neoadjuvant systemic therapy. However, recently, the results of the CREATE-X trial  and the KATHERINE trial  have been published. In patients with a Her2-negative tumour who had residual disease after neoadjuvant chemotherapy, the CREATE-X trial showed a clinical benefit (e.g. a reduction in recurrence and longer overall survival) of adjuvant treatment with capecitabine. In the KATHERINE trial, patients with a Her2-positive tumour who had residual disease after Her2-targeted neoadjuvant therapy had more clinical benefit from adjuvant treatment with TDM-1 compared to adjuvant treatment with trastuzumab. In line with these data, 83% of the panellists endorsed adjuvant treatment with capecitabine in patients with triple-negative breast cancer and residual disease (>1 cm residual tumour in the breast and/o...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« St. Gallen Consensus – Endocrine Therapy in Premenopausal Patients Next Article
Updated Interim Results of Phase 2 Trial of Pembrolizumab for High-risk NMIBC Unresponsive to BCG »
Table of Contents: BCC 2019
St. Gallen Consensus
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.